Cargando…

Author Correction: Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

Detalles Bibliográficos
Autores principales:	Han, MeiLan K., Ray, Riju, Foo, Jason, Morel, Chaienna, Hahn, Beth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674333/ https://www.ncbi.nlm.nih.gov/pubmed/34911957 http://dx.doi.org/10.1038/s41533-021-00264-6

Ejemplares similares

Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD
por: Han, MeiLan K., et al.
Publicado: (2018)

Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015)

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
por: Tebboth, Abigail, et al.
Publicado: (2016)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
por: Aziz, Mohamed Ismail Abdul, et al.
Publicado: (2018)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
por: Cohen, Joshua S, et al.
Publicado: (2016)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
por: Vanfleteren, Lowie, et al.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
por: Calzetta, Luigino, et al.
Publicado: (2017)

Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care
por: Barrecheguren, Miriam, et al.
Publicado: (2018)

Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?
por: Spina, Domenico
Publicado: (2015)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
por: Rogliani, Paola, et al.
Publicado: (2018)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: D’Urzo, Anthony, et al.
Publicado: (2019)

When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database
por: Quint, Jennifer K., et al.
Publicado: (2021)

Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2020)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
por: Miravitlles, Marc, et al.
Publicado: (2022)

Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA versus ICS/LABA in COPD Management: Findings from Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study
por: Lee, Ye Jin, et al.
Publicado: (2021)

LABA/LAMA fixed-dose combinations versus LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis
por: Chen, Ching-Yi, et al.
Publicado: (2020)

Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
por: Andreas, Stefan
Publicado: (2020)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
por: Tariq, Syed Mohammad, et al.
Publicado: (2017)

Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD
por: Gong, Yiwen, et al.
Publicado: (2022)

Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study
por: Hahn, Beth, et al.
Publicado: (2019)

And Then There Were Three: Time to Move Onward in COPD Drug Development Beyond LAMA/LABA/ICS at Last?
por: Beeh, Kai M.
Publicado: (2018)

Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2021)

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study
por: Ray, Riju, et al.
Publicado: (2019)

Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO(®) and OTEMTO(®) Studies
por: Buhl, Roland, et al.
Publicado: (2020)

Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: Huang, Wei-Chun, et al.
Publicado: (2022)

When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment
por: Cheng, Wen-Chien, et al.
Publicado: (2020)

Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies
por: Palli, Swetha R, et al.
Publicado: (2021)

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
por: Kaplan, Alan, et al.
Publicado: (2020)

Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice
por: Ding, Bo, et al.
Publicado: (2020)

Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis
por: Miravitlles, Marc, et al.
Publicado: (2022)

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017)

Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA
por: Vos, Wim, et al.
Publicado: (2016)

Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease
por: Slade, David, et al.
Publicado: (2021)

Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease
por: Yamada, Hideyasu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rq1rl5aiqvj2l0bsufig54hnr1